Product nameLanreotide peptide
Purity> 95 % SDS-PAGE.
Purity is greater than 99.0% as determined by RP-HPLC and SDS-PAGE.
Our Abpromise guarantee covers the use of ab73337 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Additional notesFor long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Constituents: 0.5% Mannitol, 0.004% Tween
ReconstitutionReconstitute in sterile 18MOhm/cm H2O at not less than 100 µg/ml, which can then be further diluted to other aqueous solutions.
RelevanceLanreotide is a a synthetic cyclic octapeptide used as a drug in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. Lanreotide is a synthetic analogue of somatostatin, a naturally occurring inhibitory hormone which blocks the release of several other hormones, including growth hormone, thyroid-stimulating hormone (TSH), insulin and glucagon. Lanreotide binds to the same receptors as somatostatin, although with higher affinity to peripheral receptors, and has similar activity. However, while somatostatin is quickly broken down in the body (within minutes), lanreotide has a much longer half-life, and produces far more prolonged effects.
ab73337 has not yet been referenced specifically in any publications.